J&J MedTech’s Dual Energy ThermoCool SmartTouch SF Catheter Gains EU Nod

Johnson & Johnson MedTech has received CE mark approval for its Dual Energy ThermoCool SmartTouch SF catheter to treat cardiac arrythmias.

The catheter is an irrigated, contact-force sensing catheter powered by the TruPulse generator. It’s also fully integrated with the Carto 3 system for electro-anatomical mapping and for tag indexing. J&J MedTech expects TruPulse generator hardware compatibility in H1 2025.

When fully approved, the platform will offer electrophysiologists the ability to switch between radiofrequency (RF) and pulsed field (PF) energy in the same catheter. The Dual Energy catheter isn’t currently approved in the U.S.

“As the number of people with AFib grows around the world, physicians are looking for integrated and flexible tools to help deliver safe, effective and efficient cardiac ablation procedures,” said Tom De Potter, M.D., Head of Electrophysiology and Associate Director of the Heart Center, OLV Hospital, Aalst, Belgium. “Both PF and RF energy have important advantages in clinical practice. With the Dual Energy THERMOCOOL SMARTTOUCH SF Catheter, having the ability to easily switch between RF and PF energy provides the flexibility to customize treatment depending on the patient anatomy and clinical need, enabling electrophysiologists to perform more targeted ablation procedures which could lead to improved outcomes for patients.”

“Based on our collaboration with electrophysiologists around the world, we know that each AFib procedure is different; having both RF and PF energy through one device will allow physicians to personalize each procedure based on patient anatomy and clinical need and offer a point-by-point workflow that many of our customers prefer,” added Jasmina Brooks, President, Electrophysiology, Johnson & Johnson MedTech. “The Dual Energy THERMOCOOL SMARTTOUCH SF Catheter offers the benefit of both energy modes in one familiar device. We are pleased to bring forward this innovation to enable electrophysiologists to deliver safe and effective procedures for patients in Europe impacted by AFib.”